Dimerix Limited (ASX: DXB)
is a clinical stage biopharmaceutical company developing therapies for diseases with unmet needs and is focusing on kidney disease. The company has advanced its Phase 3 candidate DMX-200 for focal segmental glomerulosclerosis with significant licensing agreements in place including a recent US license with Amicus Therapeutics valued up to US$590 million in upfront, development and sales milestones plus royalties. Dimerix received an upfront payment of approximately AU$48 million from Amicus and ongoing development milestone payments from other licensees.
Dimerix’s ACTION3 Phase 3 clinical trial for DMX 200 continues to recruit globally and is targeting proteinuria and eGFR outcomes with regulatory affirmation from the FDA supporting proteinuria as an acceptable endpoint for US approval. About 219 patients have been randomized or dosed to date and the open-label extension offers longer-term data and continued patient access. The company reported a strong cash position of AU$68.3 million as of June 2025 with $45.6 million cash inflows in the quarter primarily supporting continued clinical and development activities. Dimerix remains focused on maximizing the license value of DMX-200 worldwide while advancing its clinical program and pipeline.
ClearVue Technologies Limited (ASX: CPV)
has reported significant progress in Q4 FY25 which is driven by leadership changes and partnerships. Key collaborations include a two-year partnership with erbas to integrate solar façade technology into sustainable building projects and a joint venture with LandGlass to develop advanced solar vacuum insulated glazing products. These initiatives position ClearVue as a leader in energy-generating building materials.
Operational milestones during the quarter include a successful solar façade trial at the Hong Kong EMSD headquarters, demonstrating a payback period as low as 2.6 years and the potential to generate 125% of a building’s energy needs. ClearVue also secured its first major contract for Sydney’s City Tattersalls Club redevelopment and expanded into the New Zealand market through a licensing agreement with Viridian Glass. The company maintains a focus on innovation while managing cash prudently with AUD 3.7 million on hand.
Emmerson Resources Limited (ASX: ERM)
has advanced significantly in Q4 FY2025 with a robust Scoping Study confirming the White Devil Gold Deposit in Tennant Creek as a Major Mine JV asset. The updated Mineral Resource Estimate totals 4.6 Mt at 4.2 g/t gold for 611,400 ounces supporting a 7-year mine life with average annual production of 64,000 ounces and low pre-production capital costs. The study projects a strong financial outlook with operating free cash flow up to A$1.27 billion at A$5,000/oz gold and an attractive pre-tax NPV. Feasibility Study activities are ongoing which is bolstered by completed infill and geotechnical drilling.
Commercial production commenced at the Nobles CIL processing facility owned by their JV partner Tennant Mining facilitating royalty revenue streams for Emmerson. The company maintains a solid financial position with A$6.2 million cash and no debt while continuing exploration across Tennant Creek and surrounding projects to expand its high-grade gold and copper resource base
Peregrine Gold Limited (ASX: PGD)
progressed exploration activities in the quarter ended June 2025 across its Newman Gold Project and other holdings. Key achievements include completing induced polarization surveys at the Epithermal and Birdsnest prospects and an 8,100m aircore drilling program at Tin Can and Tin Can West. These initiatives followed soil sampling and geophysical surveys that identified promising gold and arsenic anomalies along strike, guiding drill targeting. Additional drilling and assays are expected to update these prospects further. A significant channel iron deposit discovery at the Coopers CID Prospect enhances Peregrine’s resource potential which is situated close to major iron ore operations and infrastructure.
The company maintained a strong financial position with approximately AUD 2.8 million in cash and liquid investments. A fully subscribed Shortfall Offer raised over AUD 0.8 million, supporting ongoing and future exploration including an upcoming ~10,000m aircore drill program at the Mallina Gold Project. Peregrine is advancing systematically toward building a major gold camp, driven by exploration and targeted drilling programs.
Vanadium Resources Limited (ASX: VR8)
has progressed its plan to unlock early cash flow from the Steelpoortdrift Vanadium Project during Q4 2025. The company signed a non-binding MoU with China Precious Asia Limited for supply of 100,000 metric tons of vanadium-rich magnetite Direct Shipping Ore per month over two years and subsequently executed a binding two-year offtake agreement pending final conditions. VR8’s strategy includes advancing DSO operations alongside development of a concentrator and exploring third-party processing options to generate near-term production while maintaining flexibility to scale full development later.
Operational activity at Steelpoortdrift was limited with cost reduction measures in place to preserve capital. The company raised A$1.2 million through an oversubscribed placement and secured convertible note conversions to strengthen its balance sheet. Environmental approvals for mining and water use are granted and rezoning applications are progressing. VR8 remains focused on capital discipline, strategic partnerships and advancing its near-term production and cash flow goals.
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
